The official blog of the Lung Institute.

Cellular Treatment Therapy for Idiopathic Pulmonary Fibrosis

25 Jan 2017
| Under Lung Disease, Pulmonary Fibrosis, Treatments | Posted by | 12 Comments

Idiopathic pulmonary fibrosis can develop for unknown causes. Here’s what you can do about it.

Idiopathic pulmonary fibrosis (IPF) is a subset of pulmonary fibrosis in which the pathology cannot be accurately determined. In short, this means that the causes for the development of the disease are unknown. Unfortunately for some, this can mean that even those who have never smoked or been around cigarettes can develop the disease. As a subset of pulmonary fibrosis diagnoses, idiopathic pulmonary fibrosis is a restrictive lung disease that occurs through the continued development of scar tissue within the lungs. As scar tissue continues to build, this increases inflammation within the airways leading to more obstructed, which ultimately restricts breathing. Although idiopathic pulmonary fibrosis is difficult to treat, there are natural treatments available to address disease symptoms as well as overall progression.

With your health in mind, the Lung Institute is here to give you an overview of Cellular Therapy for Idiopathic Pulmonary Fibrosis, how it works and what it can do for those living with IPF.

What Is Idiopathic Pulmonary Fibrosis?

As mentioned above, IPF is a form of pulmonary fibrosis in which a root cause for the disease cannot be determined. In IPF, progressive pulmonary scarring thickens and hardens airways of the lungs. As this occurs, oxygen within the lungs becomes obstructed, creating the symptom of feeling short of breath while at rest. Though the disease affects each individual differently, it’s general pathophysiology is important to understand, particularly when seeking treatment.

What Can Cellular Therapy Do for Idiopathic Pulmonary Fibrosis?

Cellular Therapy for Idiopathic Pulmonary Fibrosis

Treating IPF can be difficult because the resulting scar tissue cannot be cured or removed through traditional treatment options. Although effective medications exist to reduce the rate of fibrosis (scar tissue build-up), the development of this disease can cause other fundamental problems such as airway inflammation that must be addressed by other means. Doctors place IPF into stages to help them better understand disease severity and to develop a treatment plan.

Cellular therapy is a treatment process that extracts cells from a patient’s blood then reintroduces them intravenously, where they become trapped in the lungs. Here, the cells act as the body’s natural healing mechanism, working to relieve inflammation and promote healing. In this practice, cellular therapy not only may reduce disease symptoms but may aid in slowing the disease’s progression.

How Do I Know if Cellular Therapy for Idiopathic Pulmonary Fibrosis Is Right for Me?

When searching for a treatment for your condition, always do your research and seek out all the available options. Medications such as pirfenidone have shown great progress in reducing scar tissue development in those living with IPF. However, it’s pertinent to understand that few traditional medications are without side effects. In the case of pirfenidone, abdominal pain, dizziness, and weight loss are common.

Surgical procedures such as lung transplants and lung-volume reduction surgery can also be helpful in dramatically effecting disease progression and restoring quality of life. Nonetheless, these forms of surgery can be quite invasive, requiring weeks of further medication and pulmonary rehabilitation.

Although few treatments are perfect, cellular therapy has shown significant effects in its treatment of lung disease with few if any adverse effects. In choosing a treatment option, it’s best to weigh out the pros and cons of any treatment, and decide what’s best for you and your condition. Regardless of the treatment path you take, the key is to start as early as possible addressing the progression of the disease at its source, and minimizing further damage to your quality of life.

Moving Forward

Cellular Therapy for Idiopathic Pulmonary Fibrosis

The indeterminable cause of IPF can be difficult to deal with, but tackling the disease and its symptoms head-on is the best course of action. Challenging as IPF may be, new discoveries are made every day in the field of cellular research. Addressing the disease can mean anything from changing one’s diet to consistently exercising. Quitting smoking is also a must for those looking to improve their health and quality of life. It may be time to consider cellular therapy. Cellular therapy for idiopathic pulmonary fibrosis works to promote healing from within the lungs. Rather than only addressing the symptoms of lung disease, cellular therapy may affect disease progression and may improve quality of life and pulmonary function.

If you or a loved one suffers from a chronic disease like IPF, COPD, ILD or other symptoms of lung disease, the Lung Institute may be able to help with a variety of adult cellular therapy options. Contact us today at 888-745-6697 to see if you qualify for cellular therapy, and find out what cellular therapy could mean for you.

Interested in our article on Cellular Therapy for Idiopathic Pulmonary Fibrosis? Share your thoughts and comments below.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.